Majority of cancer survivors report unmet needs in first year after treatment
the ONA take:
The majority of cancer survivors report one or more unmet needs in the first year after primary treatment, according to a new study published online ahead of print in the journal Psycho-oncology.
For the study, researchers enrolled 255 cancer survivors who were treated at one of eight Dutch hospitals between November 2012 and January 2013. All participants were surveyed about unmet needs, demographics, disease-related characteristics, and psychosocial characteristics.
Results showed that 63% of respondents reported one or more unmet needs. The most common unmet needs reported dealt with emotional support, smoking cessation, side effect/complication management, worries over recurrence, cancer care, social support, up-to-date information, and completing work.
Researchers found that age, higher education, support program participation, anxiety, depression, and negative adjustment style were associated with more unmet needs. On the other hand, female gender, time since last treatment, and quality of life correlated with fewer unmet needs.
The majority of cancer survivors report one or more unmet needs in the first year after primary treatment.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|